

Alex Prat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8319241/alex-prat-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287
papers

23,302
citations

62
h-index

151
g-index

334
ext. papers

28,963
ext. citations

7.7
avg, IF

7.92
L-index

#	Paper	IF	Citations
287	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. <i>EBioMedicine</i> , 2022 , 75, 103801	8.8	3
286	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. <i>Cancer Research</i> , 2022 , 82, P1-18-03-P1-18-03	10.1	0
285	Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-15-01-P2-15-01	10.1	0
284	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. <i>Cancer Research</i> , 2022 , 82, P4-10-04-P4-10-04	10.1	0
283	Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3). <i>Cancer Research</i> , 2022 , 82, PD13-04-PD13-04	10.1	0
282	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). <i>Cancer Research</i> , 2022 , 82, P4-10-01-P4-10-01	10.1	0
281	Abstract TF2-3: Molecular heterogeneity in HER2+ breast cancer - can outcomes be predicted?. <i>Cancer Research</i> , 2022 , 82, TF2-3-TF2-3	10.1	0
280	Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial. <i>Cancer Research</i> , 2022 , 82, PD15-01-PD15-01	10.1	1
279	Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial). <i>Cancer Research</i> , 2022 , 82, OT2-11-07-OT2-11-07	10.1	0
278	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022 , 82, P4-06-08-P4-06-08	10.1	0
277	Abstract OT1-17-01: Solti-1716. Targeting with pembrolizumab + paclitaxel non-luminal by PAM50 hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK4/6 inhibitor treatment (TATEN trial). <i>Cancer Research</i> , 2022 , 82, OT1-17-01-OT1-17-01	10.1	0
276	Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study. <i>Cancer Research</i> , 2022 , 82, PD8-03-PD8-03	10.1	0
275	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). <i>Cancer Research</i> , 2022 , 82, OT2-27-01-OT2-27-01	10.1	0
274	Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting. <i>Cancer Research</i> , 2022 , 82, OT1-12-01-OT1-12-01	10.1	0
273	Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer. <i>Cancer Research</i> , 2022 , 82, GS2-00-GS2-00	10.1	0
272	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022 , 82, PD2-05-PD2-05	10.1	0
271	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. <i>Cancer Research</i> , 2022 , 82, P2-14-13-P2-14-13	10.1	0

270	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). <i>Cancer Research</i> , 2022 , 82, P1-07-02-P1-07-02	10.1	0
269	Abstract OT2-19-03: Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-predict). <i>Cancer Research</i> , 2022 , 82, OT2-19-03-OT2-19-03	10.1	0
268	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102392	14.4	4
267	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.. <i>European Journal of Cancer</i> , 2022 , 170, 10-16	7.5	1
266	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021 , 11, 744112	5.3	2
265	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 1669-1680	21.7	20
264	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021 , 12, 792609	8.4	
263	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. <i>JAMA Oncology</i> , 2021 ,	13.4	13
262	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021 , 7, 145	7.8	0
261	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053416	5.4	0
260	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 313	12.8	2
259	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	2
258	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021 , 5, 23	9.8	5
257	Tumor Cellularity and Infiltrating Lymphocytes (CeTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	5
256	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score 2021 , 9,		11
255	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021 , 23, 42	8.3	3
254	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. <i>Lancet Oncology, The</i> , 2021 , 22, 489-498	21.7	37
253	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 638482	5.3	5

252	A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1057-1057	2.2	1
251	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2021 , 148, 382-394	7.5	5
250	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021 , 148, 134-145	7.5	3
249	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1574-1574	2.2	0
248	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1458-1467	2.2	15
247	Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 858-871	21.7	7
246	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 149, 134-152	7.5	13
245	Current and Future Management of HER2-Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2021 , 17, 594-604	2.3	17
244	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2021 ,	7.9	3
243	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021 , 7, 73	7.8	2
242	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. <i>ESMO Open</i> , 2021 , 6, 100102	6	7
241	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021 , 150, 190-202	7.5	14
240	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188487	11.2	9
239	Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021 , 15, 350-363	7.9	6
238	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021 , 15, 887-900	7.9	6
237	The Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. <i>Cancer Research</i> , 2021 , 81, 1540-1551	10.1	0
236	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211042224	5.4	3
235	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 1	7.8	54

234	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021 , 23, 8	8.3	4
233	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 3116-3125	12.9	3
232	Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial) 2021 ,		2
231	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 12	7.8	2
230	Development and validation for research assessment of Oncotype DX [®] Breast Recurrence Score, EndoPredict [®] and Prosigna [®] . <i>Npj Breast Cancer</i> , 2021 , 7, 15	7.8	6
229	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021 , 7, 8	7.8	2
228	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology, The</i> , 2021 , 22, 212-222	21.7	64
227	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	4
226	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021 , 69, 103451	8.8	3
225	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021 , 153, 133-141	7.5	4
224	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021 , 100, 2997-3005	3	0
223	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. <i>Cancers</i> , 2021 , 13,	6.6	6
222	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
221	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 710596	5.3	2
220	Dissecting the biological heterogeneity of HER2-positive breast cancer. <i>Breast</i> , 2021 , 59, 339-350	3.6	5
219	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
218	Implementing preoperative endocrine therapy in breast cancer. <i>Lancet Oncology, The</i> , 2020 , 21, 1390-1392.	7	
217	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 45	8.3	55

216	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1089-1097	9.7	25
215	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 4688-4698	12.9	14
214	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020 , 16, 1801-1813	3.6	4
213	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. <i>Oncogene</i> , 2020 , 39, 5455-5467	9.2	6
212	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020 , 26, 2783-2788	12.9	12
211	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020 , 9,	7.9	7
210	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
209	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020 , 11, 385	17.4	36
208	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4871-4887	15.9	15
207	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI)- BYLieve study results. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1006-1006	2.2	32
206	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1011-1011	2.2	2
205	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3015-3015	2.2	3
204	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5012-5012	2.2	21
203	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 503-503	2.2	18
202	A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER+)/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS1105-TPS1105	2.2	3
201	Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 560-560	2.2	
200	Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 164-164	2.2	
199	Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 165-165	2.2	

198	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020 , 12,	6.6	3
197	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 738-745	12.9	19
196	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 33-43	21.7	52
195	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649	10.3	282
194	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020 , 12,	6.6	40
193	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
192	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 120	8.3	22
191	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , 2020 ,	24.4	96
190	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology, The</i> , 2020 , 21, 1455-1464	21.7	20
189	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148	12.9	2
188	Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2 Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020 , 26, 5843-5851	12.9	17
187	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 5820-5829	12.9	17
186	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. <i>International Journal of Cancer</i> , 2020 , 146, 262-271	7.5	17
185	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
184	Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. <i>Clinical and Translational Oncology</i> , 2020 , 22, 953-955	3.6	4
183	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020 , 26, 3720-3731	12.9	10
182	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , 2019 , 120, 54-64	7.5	13
181	PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. <i>Frontiers in Oncology</i> , 2019 , 9, 707	5.3	7

180	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology, The</i> , 2019 , 20, 1360-1369	21.7	68
179	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019 , 21, 108	8.3	11
178	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019 , 25, 2975-2987	12.9	51
177	Chromosome 12p Amplification in Triple-Negative/Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019 , 79, 4258-4270	10.1	6
176	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 103-114	4.4	17
175	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 303	5.3	3
174	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. <i>Annals of Oncology</i> , 2019 , 30, 927-933	10.3	22
173	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 2019 , 7, 90		40
172	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. <i>Translational Research</i> , 2019 , 208, 73-84	11	3
171	The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019 , 145, 1970-1981	7.5	8
170	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. <i>Molecular Cancer Research</i> , 2019 , 17, 2063-2076	6.6	12
169	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. <i>European Journal of Radiology</i> , 2019 , 117, 132-139	4.7	6
168	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1050-1050	2.2	1
167	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 544-544	2.2	5
166	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 571-571	2.2	4
165	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 574-574	2.2	4
164	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 575-575	2.2	1
163	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4588-TPS4588	2.2	5

162	Cell plasticity associated to taxane-resistance in preclinical cell models and in circulating tumor cells from metastatic castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 238-238	2.2	1
161	ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 207-207	2.2	
160	The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as a biomarker of taxane resistance in castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 235-235 ^{2.2}		
159	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019 , 30, 921-926	10.3	38
158	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019 , 24, 893-900	5.7	12
157	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. <i>Frontiers in Oncology</i> , 2019 , 9, 1178	5.3	4
156	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-6	3.6	4
155	SEOM clinical guidelines in early stage breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019 , 21, 18-30	3.6	22
154	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019 , 17, 8	11.4	15
153	Coamplification of protects -amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E2594-E2603	11.5	15
152	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER breast cancer. <i>Nature Cell Biology</i> , 2018 , 20, 211-221	23.4	71
151	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. <i>Acta Oncologica</i> , 2018 , 57, 38-43	3.2	15
150	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018 , 29, 170-177	10.3	45
149	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018 , 24, 5820-5829	12.9	47
148	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) <i>Annals of Oncology</i> , 2018 , 29, 1634-1657	10.3	645
147	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018 , 67, 63-70	14.4	45
146	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. <i>Annals of Oncology</i> , 2018 , 29, 2121-2128	10.3	41
145	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 771-781	35.1	107

144	Molecular Tumor Boards. <i>Breast Care</i> , 2018 , 13, 141-143	2.4	2
143	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III	7.5	3
142	Abstract P2-09-04: Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer 2018 ,		2
141	Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer 2018 ,		3
140	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) 2018 ,		10
139	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3887-3905	15.9	41
138	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1025-1025	2.2	2
137	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompleEment-1 trial..	2.2	2
136	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 507-507	2.2	4
135	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 500-500	2.2	8
134	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1101-TPS1101	2.2	4
133	A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3105-TPS3105	2.2	2
132	Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 438-438	2.2	3
131	Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e12634-e12634	2.2	2
130	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16579-e16579	2.2	
129	Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3553-3553	2.2	
128	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3076-3076	2.2	
127	Predictive model of complexity in early palliative care: a cohort of advanced cancer patients (PALCOM study). <i>Supportive Care in Cancer</i> , 2018 , 26, 241-249	3.9	16

126	Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. <i>Annals of Oncology</i> , 2018 , 29, viii61	10.3	4
125	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017 , 23, 649-657	12.9	75
124	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 119-124	3.6	17
123	Pertuzumab Use in the Adjuvant Setting: Why Not?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1138	2.2	
122	Identification of , , and Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017 , 63, 751-760	5.5	45
121	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 545-554	21.7	175
120	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2213-2221	10.1	109
119	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017 , 77, 3540-3550	10.1	213
118	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017 , 8, 1392-1407	8	53
117	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017 , 23, 3035-3044	12.9	17
116	What's New in Biology. <i>Breast</i> , 2017 , 36, S29	3.6	
115	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017 , 21, 2183-2197	10.6	41
114	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 1777-1786	8.7	43
113	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017 , 34 Suppl 1, S19-S26	3.6	35
112	miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. <i>Clinical Cancer Research</i> , 2017 , 23, 1091-1103	12.9	79
111	Vasculitic neuropathy induced by pembrolizumab. <i>Annals of Oncology</i> , 2017 , 28, 433-434	10.3	30
110	Abstract P1-09-09: Efficacy and gene expression results from SOLT11007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer 2017 ,		2
109	Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)? (GEICO 1205/NOVA TRIAL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5508-5508	2.2	8

108	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 21930-21937	3.3	10
107	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. <i>Clinical Cancer Research</i> , 2016 , 22, 560-6	12.9	57
106	Tankyrase Inhibition Blocks Wnt/ β -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 644-56	12.9	114
105	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016 , 2, 1287-1294	13.4	65
104	Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study. <i>Current Medical Research and Opinion</i> , 2016 , 32, 835-9	2.5	5
103	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 81-9	4.4	35
102	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 709-713	10.2	48
101	Home management of acute medical complications in cancer patients: a prospective pilot study. <i>Supportive Care in Cancer</i> , 2016 , 24, 2129-2137	3.9	6
100	GeneFu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. <i>Bioinformatics</i> , 2016 , 32, 1097-9	7.2	150
99	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. <i>Oncotarget</i> , 2016 , 7, 67956-67965	3.65	4
98	Molecular Classification of Breast Cancer 2016 , 203-219		0
97	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14552-e14552	2.2	
96	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3033-3033	2.2	
95	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016 , 1, e000032	6	5
94	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. <i>Annals of Oncology</i> , 2016 , 27, 1867-73	10.3	68
93	PG 3.01 Clinical implications of the intrinsic molecular subtypes. <i>Breast</i> , 2015 , 24, S5-S6	3.6	3
92	Response. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	
91	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015 , 7, 283ra51	17.5	204

90	Defining breast cancer intrinsic subtypes by quantitative receptor expression. <i>Oncologist</i> , 2015 , 20, 474-87	9.7	102
89	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015 , 31, 1129-37	2.5	25
88	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015 , 24 Suppl 2, S26-35.6	3.6	450
87	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv256	9.7	60
86	Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes: waiting for TAILORx and RxPONDER. <i>Annals of Oncology</i> , 2015 , 26, 70-74	10.3	9
85	SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. <i>Oncogene</i> , 2015 , 34, 671-80	9.2	58
84	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015 , 13, 303	11.4	87
83	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. <i>Molecular Oncology</i> , 2015 , 9, 1081-90	7.9	25
82	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9069-9069	2.2	9
81	PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS642-TPS642	2.2	1
80	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015 , 6, 28173-82	3.3	20
79	Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11049-11049	2.2	0
78	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 569-569	2.2	
77	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014 , 8, 20-6	7.9	34
76	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1532-41	8.7	82
75	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 557-66	4.4	48
74	Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 185-91	4.4	33
73	How many etiological subtypes of breast cancer: two, three, four, or more?. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	142

72	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. <i>BMC Cancer</i> , 2014 , 14, 302	4.8	37
71	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. <i>Clinical Cancer Research</i> , 2014 , 20, 511-21	12.9	143
70	Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. <i>Stem Cell Reports</i> , 2014 , 2, 633-47	8	69
69	The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. <i>Cell Reports</i> , 2014 , 6, 1059-1072	10.6	109
68	PELO negatively regulates HER receptor signalling and metastasis. <i>Oncogene</i> , 2014 , 33, 1190-7	9.2	6
67	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. <i>Annals of Oncology</i> , 2014 , 25, 552-563	10.3	242
66	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	132
65	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	30
64	Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. <i>Cancer Research</i> , 2014 , 74, 7406-17	10.1	30
63	Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. <i>Oncologist</i> , 2014 , 19, 1076-83	5.7	85
62	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. <i>Clinical and Translational Oncology</i> , 2014 , 16, 386-94	3.6	14
61	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. <i>Clinical and Experimental Metastasis</i> , 2014 , 31, 33-45	4.7	38
60	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1418-1418	15.9	78
59	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 237-55	4.4	132
58	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 203-9	2.2	376
57	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 373-82	4.4	80
56	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. <i>Cell Reports</i> , 2013 , 4, 1116-30	10.6	447
55	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. <i>Nature Communications</i> , 2013 , 4, 1393	17.4	184

54	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 457-66	4.4	78
53	Predicting drug responsiveness in human cancers using genetically engineered mice. <i>Clinical Cancer Research</i> , 2013 , 19, 4889-99	12.9	51
52	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. <i>Oncologist</i> , 2013 , 18, 123-33	5.7	376
51	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E1301-10	11.5	58
50	SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. <i>Molecular and Cellular Biology</i> , 2013 , 33, 3011-25	4.8	40
49	A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. <i>Clinical Cancer Research</i> , 2013 , 19, 6787-801	12.9	63
48	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. <i>Cancer Research</i> , 2013 , 73, 4885-97	10.1	331
47	Reply to Y.Yamamoto et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2517-8	2.2	2
46	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. <i>Scientific Reports</i> , 2013 , 3, 3544	4.9	42
45	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2551-63	15.9	86
44	ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4329-43	15.9	43
43	Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11021-11021	2.2	
42	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 301-6	4.4	117
41	Defining the cellular precursors to human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2772-7	11.5	160
40	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. <i>Cancer Discovery</i> , 2012 , 2, 1036-47	24.4	418
39	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. <i>BMC Medical Genomics</i> , 2012 , 5, 44	3.7	199
38	Comprehensive molecular portraits of human breast tumours. <i>Nature</i> , 2012 , 490, 61-70	50.4	8025
37	USP15 stabilizes TGF- β receptor I and promotes oncogenesis through the activation of TGF- β signaling in glioblastoma. <i>Nature Medicine</i> , 2012 , 18, 429-35	50.5	280

36	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 523-35	4.4	165
35	Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. <i>Cancer Cell</i> , 2012 , 21, 626-641	24.3	92
34	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. <i>Annals of Oncology</i> , 2012 , 23, 2866-2873	10.3	103
33	The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 221-6	11.5	47
32	Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. <i>British Journal of Cancer</i> , 2012 , 107, 1249-56	8.7	53
31	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1541-52	15.9	161
30	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABC. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1008-1008	2.2	12
29	Gene expression-based predictors of chemotherapy response in basal-like breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10500-10500	2.2	2
28	Practical implications of gene-expression-based assays for breast oncologists. <i>Nature Reviews Clinical Oncology</i> , 2011 , 9, 48-57	19.4	205
27	Deconstructing the molecular portraits of breast cancer. <i>Molecular Oncology</i> , 2011 , 5, 5-23	7.9	841
26	MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. <i>Cell Stem Cell</i> , 2011 , 8, 525-37	18	84
25	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. <i>Breast Cancer Research</i> , 2011 , 13, R125	8.3	63
24	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2342-9	2.2	379
23	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. <i>BMC Medical Genomics</i> , 2011 , 4, 3	3.7	104
22	Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. <i>BMC Medical Genomics</i> , 2011 , 4, 77	3.7	33
21	Molecular classification of triple-negative tumors. <i>Breast Cancer Research</i> , 2011 , 13,	8.3	78
20	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3761-6	11.5	241
19	Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. <i>Journal of Clinical Oncology</i> , 2011 , 29, 502-502	2.2	3

18	Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 529-529	2.2	7
17	Clinical implementation of the intrinsic subtypes of breast cancer. <i>Lancet Oncology, The</i> , 2010 , 11, 718-9; author reply 720-1	21.7	79
16	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. <i>Breast Cancer Research</i> , 2010 , 12, R68	8.3	1428
15	Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. <i>Annals of Oncology</i> , 2009 , 20, 294-7	10.3	27
14	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. <i>Lung Cancer</i> , 2009 , 66, 257-61	5.9	16
13	Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. 2009 ,		9
12	Update on novel therapeutic agents for cervical cancer. <i>Gynecologic Oncology</i> , 2008 , 110, S72-6	4.9	54
11	Acute severe hypothyroidism induced by sunitinib. <i>Radiotherapy and Oncology</i> , 2008 , 89, 124-5	5.3	2
10	Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. <i>Annals of Oncology</i> , 2008 , 19, 327-31	10.3	43
9	Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1771-2; author reply 1772	2.2	4
8	The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 531-42		136
7	A rare case of malignant solitary fibrous tumor of the spinal cord. <i>Spine</i> , 2008 , 33, E397-9	3.3	47
6	Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. <i>Head and Neck</i> , 2008 , 30, 680-3	4.2	69
5	Acute lung injury associated with docetaxel and bevacizumab. <i>Clinical Oncology</i> , 2007 , 19, 803-5	2.8	10
4	Hepatic pneumatosis as a complication of an abdominal desmoid tumor. <i>Journal of Clinical Oncology</i> , 2007 , 25, 897-8	2.2	3
3	New approaches in angiogenic targeting for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5857-66	5.6	46
2	Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (EOC). <i>Journal of Clinical Oncology</i> , 2007 , 25, 16007-16007	2.2	227
1	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver		1

